UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

Journal of medicinal chemistry, 2018-04, Vol.61 (7), p.2837-2864

2018

Volltextzugriff (PDF)

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer

Clinical cancer research, 2021-11, Vol.27 (21), p.5760-5770

2021

Volltextzugriff (PDF)

LSZ in action: extracting form factors from correlators nonperturbatively in 2d ϕ4 theory

The journal of high energy physics, 2024-03, Vol.2024 (3), p.154, Article 154

2024

Volltextzugriff (PDF)

Selenium Analogue of LSZ102 as a Highly Potent ER‐α Binder

European journal of organic chemistry, 2023-07, Vol.26 (27), p.n/a

2023

Volltextzugriff (PDF)

Complete Solution of the LSZ Model via Topological Recursion

Communications in mathematical physics, 2023-08, Vol.401 (3), p.2845-2899

2023

Volltextzugriff (PDF)

From Faddeev–Kulish to LSZ. Towards a non-perturbative description of colliding electrons

Nuclear physics. B, 2017-12, Vol.925, p.455-469

Dybalski, Wojciech

2017

Volltextzugriff (PDF)

Synthesis Development of the Selective Estrogen Receptor Degrader (SERD) LSZ102 from a Suzuki Coupling to a C–H Activation Strategy

Organic process research & development, 2020-08, Vol.24 (8), p.1405-1419

2020

Volltextzugriff (PDF)

Species-dependent hepatic and intestinal metabolism of selective oestrogen receptor degrader LSZ102 by sulphation and glucuronidation

Xenobiotica, 2022-01, Vol.52 (1), p.26-37

2022

Volltextzugriff (PDF)

Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products

Forensic toxicology, 2023-07, Vol.41 (2), p.294-303

2023

Volltextzugriff (PDF)

Knowledge-driven method: a tool for landslide susceptibility zonation (LSZ)

Geology, ecology, and landscapes, 2023-01, Vol.7 (1), p.1-15

2023

Volltextzugriff (PDF)

Abstract PD7-09: A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD7-09-PD7-09

2020

Volltextzugriff (PDF)

Abstract P4-10-07: Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-10-07

2020

Volltextzugriff (PDF)

LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)

Annals of oncology, 2020-05, Vol.31, p.S62-S62

2020

Volltextzugriff (PDF)

Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.922-922

2019

Volltextzugriff (PDF)

Abstract 4769: Gene expression profiling of response to short- and long-term treatment of LSZ102 in MCF7 cells

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4769-4769

2019

Volltextzugriff (PDF)

Return of the lysergamides. Part II: Analytical and behavioural characterization of N 6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)

Drug testing and analysis, 2017-01, Vol.9 (1), p.38-50

2017

Volltextzugriff (PDF)

LSZ-reduction, resonances and non-diagonal propagators: Gauge fields

Nuclear physics. B, 2018-10, Vol.935, p.40-82

Lewandowski, Adrian

2018

Volltextzugriff (PDF)

LSZ-reduction, resonances and non-diagonal propagators: Fermions and scalars

Nuclear physics. B, 2018-12, Vol.937, p.394-421

Lewandowski, Adrian

2018

Volltextzugriff (PDF)

Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-03-01-OT1-03-01

2019

Volltextzugriff (PDF)

Abstract PD1-08: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD1-08-PD1-08

2019

Volltextzugriff (PDF)

Enhancing Unconfined Compressive Strength prediction in geotechnical engineering: a novel approach using LSZO and LSWG optimization

Smart science, 2024-10, p.1-19

2024

Volltextzugriff (PDF)

GIS-based landslide susceptibility zonation (LSZ) mapping of Darjeeling Himalaya, India using weights of evidence (WoE) model

Arabian journal of geosciences, 2023, Vol.16 (7), Article 421

2023

Volltextzugriff (PDF)

Selection of weightages for causative factors used in preparation of landslide susceptibility zonation (LSZ)

Geomatics, natural hazards and risk, 2018-01, Vol.9 (1), p.471-487

2018

Volltextzugriff (PDF)

LSZ in action: extracting form factors from correlators nonperturbatively in 2d ϕ 4 theory

The journal of high energy physics, 2024-03, Vol.2024 (3), p.1-27

2024

Volltextzugriff (PDF)

Abstract P5-21-04: Phase I/Ib study of the SERD LSZ102 alone or in combination with ribociclib in ER+ breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-04

2018

Volltextzugriff (PDF)

1 – 25 von 11.992

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.926)
Mit Volltextzugriff
(8.547)

Publikationsform

8 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(118)
... seit 30 Tagen
(30)

Menü

Weitere Dienste

Einstellungen

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer

LSZ in action: extracting form factors from correlators nonperturbatively in 2d ϕ4 theory

Selenium Analogue of LSZ102 as a Highly Potent ER‐α Binder

Complete Solution of the LSZ Model via Topological Recursion

From Faddeev–Kulish to LSZ. Towards a non-perturbative description of colliding electrons

Synthesis Development of the Selective Estrogen Receptor Degrader (SERD) LSZ102 from a Suzuki Coupling to a C–H Activation Strategy

Species-dependent hepatic and intestinal metabolism of selective oestrogen receptor degrader LSZ102 by sulphation and glucuronidation

Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products

Knowledge-driven method: a tool for landslide susceptibility zonation (LSZ)

Abstract PD7-09: A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)

Abstract P4-10-07: Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC

LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)

Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER

Abstract 4769: Gene expression profiling of response to short- and long-term treatment of LSZ102 in MCF7 cells

Return of the lysergamides. Part II: Analytical and behavioural characterization of N 6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)

LSZ-reduction, resonances and non-diagonal propagators: Gauge fields

LSZ-reduction, resonances and non-diagonal propagators: Fermions and scalars

Abstract PD1-08: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

Enhancing Unconfined Compressive Strength prediction in geotechnical engineering: a novel approach using LSZO and LSWG optimization

GIS-based landslide susceptibility zonation (LSZ) mapping of Darjeeling Himalaya, India using weights of evidence (WoE) model

Selection of weightages for causative factors used in preparation of landslide susceptibility zonation (LSZ)

LSZ in action: extracting form factors from correlators nonperturbatively in 2d ϕ 4 theory

Abstract P5-21-04: Phase I/Ib study of the SERD LSZ102 alone or in combination with ribociclib in ER+ breast cancer

Suchergebnisse filtern